Roivant Sciences (ROIV) Operating Leases (2021 - 2026)

Roivant Sciences (ROIV) has 6 years of Operating Leases data on file, last reported at $107.4 million in Q1 2026.

• Quarterly Operating Leases rose 18.94% year-over-year to $107.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.4 million (up 18.94% YoY) and the FY2026 annual result came in at $107.4 million, up 18.94% from the prior year.
• Operating Leases rose to $107.4 million in Q1 2026, from $98.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $107.4 million in Q1 2026 to a low of $45.0 million in Q1 2024.
• A 5-year average of $67.0 million and a median of $54.9 million in 2022 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases retreated 17.06% — and 2025, when it jumped 100.64%.
• Tracing ROIV's Operating Leases over 5 years: stood at $54.9 million in 2022, then declined by 14.32% to $47.1 million in 2023, then surged by 92.27% to $90.5 million in 2024, then grew by 8.87% to $98.5 million in 2025, then gained by 9.07% to $107.4 million in 2026.
• The last three Operating Leases figures came in at $107.4 million (Q1 2026), $98.5 million (Q4 2025), and $89.8 million (Q3 2025), per Business Quant data.